相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1929
进行中（未招募）
1
50.0%
已完成
1
50.0%
暂无批准数据
- Cure Alzheimer's Fund (CureAlz) has appointed Stephanie Wasco as its new Executive Vice President of Marketing and Communications, effective August 20, 2026. - Wasco will lead the nonprofit's brand, marketing, and communications strategy to advance awareness of its mission to fund research aimed at preventing, slowing, or reversing Alzheimer's disease. - CureAlz has provided $270 million to 400 leading researchers since its founding in 2004 and holds a Four-Star Charity Navigator rating for 14 consecutive years. - Wasco previously served as Senior Vice President and Head of Communications for advanced markets at Biocon Biologics.
- Longevica Therapeutics has appointed Dr. Prasun Mishra, a former Genentech/Roche and NIH executive, as CEO to transition its longevity discovery platform into clinical development. - The appointment follows completion of a four-year, $13 million in vivo screen at The Jackson Laboratory that tested 1,033 small-molecule compounds across more than 16,000 mice over their natural lifespans. - Deep mechanistic analysis of the dataset identified two previously uncharacterized biological mechanisms tied to mammalian lifespan extension, laying the foundation for IND-enabling studies. - The company will prioritize age-related metabolic dysfunction and systemic fibrotic disorders while pursuing AI-driven target discovery, biopharma partnerships, and a veterinary medicine pathway.
- The global optogenetics actuators and sensors market is projected to grow from USD 1.3 billion in 2026 to USD 4.2 billion by 2036 at a 12.7% CAGR, according to Future Market Insights. - NIH allocated USD 321 million for the BRAIN Initiative in fiscal 2025, reinforcing federal support for platform tools and neurotechnologies that underpin optogenetics research. - Optogenetic actuators are expected to hold a 43.0% product share in 2026, while neuroscience research accounts for 48.0% of application demand and academic institutes capture 51.0% of the end-user market. - Spectral interference, tissue heating, and variable expression remain key technical restraints that complicate qualification across animal cohorts and research sites.
- Children's Hospital of Philadelphia received up to $38.9 million over five years to develop personalized gene-editing therapies for four groups of rare liver-related genetic disorders, including urea cycle disorders and hemophilia A. - The Jackson Laboratory and Broad Institute secured up to $34.5 million for the PERC platform targeting pediatric epilepsies, initially focusing on alternating hemiplegia of childhood and Dravet syndrome. - Both awards come through ARPA-H's THRIVE initiative, which aims to transform individualized gene-editing approaches into scalable, repeatable platforms for rare disease treatment. - The programs will leverage base editing, prime editing, and lipid nanoparticle delivery systems while addressing regulatory, manufacturing, and access challenges for ultra-rare conditions.
- MaineHealth secured $2 million from the Maine Technology Institute to create the state's first Clinical Research Unit, a 5,500-square-foot facility at Maine Medical Center Biddeford scheduled to open in 2027. - The dedicated research facility will enable 20-40 patients in its first year to participate in clinical trials closer to home, eliminating the need to travel to Boston for certain studies. - The unit will focus on common Maine conditions including oncology, cardiovascular disease, infectious disease, and mental health, featuring observation rooms for overnight stays and dedicated pharmacy services. - The facility represents a strategic investment in Maine's life sciences infrastructure, providing early-career researchers with expanded opportunities while improving health equity for rural communities.
- Researchers at The Jackson Laboratory and MIT have developed a microneedle patch that painlessly collects immune cells and inflammatory signals directly from skin tissue within 15-30 minutes. - The FDA-approved polymer device captures resident memory T cells and other immune components that traditional blood tests often miss, offering new insights into tissue-based immune responses. - Early human testing shows the patch successfully collected immune cells in allergic contact dermatitis cases, with results matching more invasive biopsy methods. - The technology could transform monitoring of autoimmune diseases, vaccine responses, and cancer treatments while enabling potential at-home immune system tracking.
- The Jackson Laboratory received up to $30 million from ARPA-H to develop CARDIOVERSE, an AI-powered platform using virtual hearts to predict drug cardiotoxicity before human trials. - The initiative combines genetically diverse mouse models and human stem cells with artificial intelligence to create digital twins of the human heart that can simulate drug responses across different patient populations. - CARDIOVERSE aims to address cardiotoxicity, which causes up to 15% of drug withdrawals after FDA approval and represents a leading cause of clinical trial failure. - The platform could reduce reliance on expensive large-animal studies and help smaller biotech companies advance drug candidates to human trials more efficiently.
- The Jackson Laboratory has completed its acquisition of the New York Stem Cell Foundation, creating a powerful nonprofit platform that combines genetics, stem cell science, and AI-driven analytics for biomedical discovery. - The integration merges JAX's mouse modeling expertise with NYSCF's Global Stem Cell Array® robotic platform, enabling large-scale, reproducible stem cell research and patient-specific disease modeling. - This unified platform aims to accelerate therapeutic development for diseases including Alzheimer's, ALS, cancer, diabetes, and Parkinson's by improving early-stage research predictability and reducing clinical trial failures.
- Kernal Bio received up to $48 million from ARPA-H to advance its in vivo CAR-T cell therapy program KR-402, targeting multiple sclerosis and B-cell malignancies including acute lymphoblastic leukemia and large B-cell lymphoma. - The company's mRNA 2.0 platform uses selective mRNA and targeted lipid nanoparticles to reprogram T cells directly inside the body, potentially reducing manufacturing costs by 100-fold compared to traditional ex vivo CAR-T therapies. - The in vivo approach eliminates the need for toxic lymphodepletion procedures and reduces the three-week vein-to-vein turnaround time associated with current CAR-T treatments. - Kernal Bio will collaborate with Stanford University School of Medicine, Dana-Farber Cancer Institute, and The Jackson Laboratory to develop this next-generation cell therapy technology.
